Drugs / Vi-CRM197
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01123941 | May → Jun 2010 | typhoid fever | Novartis | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01437267 | Oct 2011 → Aug 2012 | typhoid fever | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT01229176 | Mar 2011 → Jun 2012 | typhoid fever | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT01193907 | Oct → Nov 2010 | typhoid fever | Novartis | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vi-CRM₁₉₇ | “The Novartis Vaccines Institute for Global Health developed a conjugate vaccine (Vi-CRM₁₉₇) for infant vaccination concomitantly with EPI vaccines, either starting at 6 weeks...” PMID 21980445 ↗ Sep 2011 |
| Known as | NVGH Vi-CRM197 | “Biological: NVGH Vi-CRM197” NCT01123941 ↗ |
| Modality | Vaccine | “NVGH Vi-CRM197 conjugate vaccine” NCT01123941 ↗ |